Egleston Law Firm announces an investigation into possible breaches of
fiduciary duty in connection with the proposed acquisition of Martek
Biosciences Corporation (NASDAQ: MATK) (“Martek” or the “Company”) by
Royal DSM N.V. (“DSM”) in an all cash tender offer valued at
approximately $1.087 billion.
Under the terms of the definitive agreement, Martek shareholders will
receive $31.50 in cash for each share they own of the Company’s common
stock. The acquisition is structured as an all-cash tender offer to be
followed by a merger in which each remaining share of Martek common
stock would be converted into the same cash per share price paid in the
tender offer. The tender offer is expected to commence between January
10 and January 25, 2011, and to close in February 2011. The acquisition
is expected to close in the first or second quarter of 2011. The
investigation is focused on whether the proposed deal provides adequate
value to Martek’s shareholders.
If you are a shareholder of Martek and would like more information about
our investigation, please contact Gregory M. Egleston, Esq. by telephone
at (646) 227-1700 or by e-mail at email@example.com
or visit www.gme-law.com.
ATTORNEY ADVERTISING. Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
Egleston Law Firm
Gregory M. Egleston, Esq., 646-227-1700